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I - INTRODUCTION 
 1- Neonatal screening for a metabolic disease must address a frequent pathology for 
which there is an efficient treatment and only if this treatment is applied early in life. 
 2- The screening must be universal 
 3- Urine sample screening test 
II - PHENYLKETONURIA 
 1- Epidemiology 
 2- Physiopathology 
 3- Hyperphenylalaninemia 
 4- Dihydropteridin reductase deficiency 
 5- Hyperphenylalaninemia can be detected after a few of days of normal feeding 
 6- Clinical forms, differential diagnosis 
 7- Treatment 
 8- Dihydropteridine reductase deficiency 
III - CONGENITAL HYPOTHYROIDISM  
 1-Epidemiology 
 2-Neonatal screening  
 3-Dosage methods 
 4- Treatment 
IV COROLLARY 
 1- Overview of international practices 
 2- Overview of diagnosable diseases 
 3- Treatment 
 4- Diseases with apparent symptoms during the post natal period  
 5- Genetic counselling / informed consent 
 6- Development  
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I - INTRODUCTION 
1- Neonatal screening for a metabolic disease must 
address a frequent pathology for which there is an 
efficient treatment and only if this treatment is 
applied early in life. 
The universal screening of phenylketonuria and 
hypothyroidism are good examples of this concept. 
Those are diseases that affect approximately 1 out of 
10,000 neonates, leading to a serious encephalopathy 
during the neonatal period if no efficient treatment is 
applied and for which there are screening tests that are: 
- specific 
- sensitive 
- not costly and to which there is a good response 
- this leads to the establishment of regional and 
national infrastructures 
- including accredited specialized laboratories. 
2- The screening must be universal 
- Unless otherwise specified all newborns must 
have access to the program 
- the laboratory personnel and the clinicians 
analyse results, control positive and dubious 
results, carry on the necessary investigations and 
establish a treatment 
- in practice: these tests are performed at the time 
of discharge of the mother from the maternity, 
(between the 2nd and 7th day after delivery 
- the metabolic disorder is then diagnosable, 
- before any clinical sign appears in the newborn 
- the blood is drawn by heel prick on a filter paper 
identified with the newborn hospital card vital 
information. 
3- Urine sample screening test 
- a few health services have adopted the urinary 
screening that is done around the 3rd week of life 
from a filter paper containing a urine spot taken 
from a damp diaper. The dried filter paper is 
mailed to the screening centre by the parents. 
- This urinary screening test was initiated in the 
Province of Quebec in the early seventies; it is 
one of the few programs that exist in the world. It 
allows the early detection of organic acid 
disorders, or other disorders which could have 
been missed by the blood tests done during the 
first week of life if the protein intake was 
insufficient to reveal a metabolic block.  
II - PHENYLKETONURIA 
1- Epidemiology 
- autosomal recessive disease 
- risk of recurrence: ¼ 
- q gene frequency = 1% 





- Phenylalanine hydroxylase deficiency 
- a classical form that is treatable. 
3- Hyperphenylalaninemia 
- increase in number of catabolites of 
Phenylalanine (Phe) 
- deficit of metabolites downstream to the 
enzyme (tyrosine, dopa, melanin…). 
4- Dihydropteridin reductase deficiency 
- Severe form with: 
- hyperphenylalaninemia, and hypertyrosinemia 
- serotonine and norepinephrenine deficiency 
downstream to this enzyme 
- evolution without treatment: within a few weeks 
digestive problems, skin lesions and convulsions 
are observed, with a delay in psychomotor 
development, deteriorated general health leading 
to death in absence of treatment. One must obtain 
blood and urine samples and a liver biopsy for a 
post mortem diagnosis and early treatment of a 
close relative, undiagnosed brother or sister. If the 
treatment was instituted too late the child will 
develop a profound psychomotor retardation (IQ= 
29 to 50) a with a number of neurological 
disorders and hypopigmentation. 
5- Hyperphenylalaninemia can be detected after a 
few of days of normal feeding 
- normal Phenylalanine level <4mg/100 ml 
(Other ref: <300mM) 
- the test result is available within 15 days 
- automated fluorometric blood dosage of 
phenylalanine. 
Note: the tests will detect hyperphenylalaninemia but 
not its cause: it could be a true enzymatic deficien y or 
transitory, (prematurity manifested by hyperphenyl-
alaninemia and hypertyrosinemia or excess nutritional 
phe intake). The diagnosis must be confirmed by more 
precise blood tests. 
6- Clinical forms, differential diagnosis 
- deficit in dihydropteridine reductase: 
hyperphenylalaninemia 
- <20mg/100ml; rapid lowering of Phe level with 
the diet but unpreventable neurological 
deterioration. 
7- Treatment 
Phenylketonuria. Hypoprotein diet with a low Phe 
content to assure the child will have the intake neds in 
Phe (to avoid overloading or deficit…..biological 
control: 3mg/100ml < Phe < 10mg/100ml (other ref: 
100mM to 300mM). 
- neonatal diet. Low Phe diet during infancy and 
if possible kept during adulthood; strict 
control of mother's Phe level: if it is to high 
during pregnancy there is an increased risk of 
foetal demise. 
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8- Dihydropteridine reductase deficiency 
Treatment: substitution by tryptophane and serotonine, 
close follow up, genetic counselling and psychological 
aid. 
III - CONGENITAL HYPOTHYROIDISM 
1-Epidemiology: 0. 03 to 0.06 % births 
2-Neonatal screening 
In most programs TSH is measured on filter papers. If 
TSH is elevated the diagnosis must be confirmed with 
plasma measurements (TSH, free T4, total T3). 
3-Dosage methods 
- Dosage of TSH (thyroid stimulating hormone), 
normal level <12µU/ml; pathological level> 
30µU/ml; intermediate level 15-30µU/ml : 
control indicated. 
- Dosage of T4 (thyroxine or Tetraiodo- thyronine) 
by radioimmunology. 
- Identifies all thyroid primary and secondary 
deficits but presence of false positive, (3% of 
positive results are detected by this method). 
- Hypothalamo-hypophysary disorders are not 
detected by this method. 
- Confirmation by complementary tests: 
scintigraphy and measure of maternal thyroid 
antibodies and dosage of thyroglobulin. 
4- Treatment:  
Initially 10µg/kg de L Thyroxine with periodical 
controls of thyroid function every 3 months until one 
year of age then every 6 months until three years of age 
and thereafter every year. 
IV COROLLARY 
1- Overview of international practices 
An overview of measures taken throughout the world 
confirms that neonatal screening was initiated in 
several countries in different ways and in most cases in 
relation to the populations more at risk to develop a 
metabolic disease like phenylketonuria hypothyroidism 
and/or cystic fibrosis (mucoviscidosis). 
This is particularly true for blood dyscrasias such as 
sickle cell anemia and thalassemia, two diseases that 
are more frequent in the Mediterranean countries, 
Africa and Asia. Tyrosinemia is frequent in Finland 
and the Quebec Saguenay region. This implies that 
specific screening tests are developed according to the 
mutant gene frequencies found in certain populations 
that often live in isolates. 
Neonatal screening programs have been adopted by 
several countries. For instance neonatal screening for 
phenylketonuria and hypothyroidism are current 
practice in several countries of North America, Europe, 
in Japan New Zeland, Australia, Israel and more 
recently in China and South America (WB Hanley, 
personal communication). 
TANDEM MASS SPECTROMETRY 
The development of tandem mass spectrometry 
(MS/MS) has allowed in recent years the detection, 
confirmation of diagnosis and the follow up of 
newborns affected with phenylketonuria, hepatorenal 
tyrosinemia and MCAD (medium-chain acyl co-
enzyme A dehydrogenase) deficiency and will probably 
be a screening tool for several metabolic disorders such 
as organic acidurias and urea cycle defects.  
2- Overview of diagnosable diseases 
Approximately 2 to 40 metabolic diseases can be 
detected in the neonatal period. 
The majority are in need of medical intervention, some 
will need a close surveillance. 
- Hereditary metabolic diseases: Phenyl-ketonuria, 
hepatorenal tyrosinemia, organic aciduria, fatty 
acid oxidation defects…. 
- Blood dyscrasias: Thalassemia, sickle cell anemia 
- Endocrine diseases: Hypothyroidism, adrenal 
hiperplasia 
- Infectious diseases: Human immuno deficiency 
virus (HIV) 
- Others: 
o Hearing déficit 
o Cystic fibrosis (mucoviscidosis) 
o Duchenne muscular dystrophy 
 i- Hearing deficit 
It is generally accepted that neonatal screening can 
apply to non metabolic diseases like hearing deficits. 
A number of health services have initiated hearing 
evaluation by otoacoustic emissions in the neonatal 
period for newborns aged from 30 months of gestation 
to full term. 
This neonatal screening for hearing has the same goal 
as the screening programs for cystic fibrosis and 
Duchenne muscular dystrophy (DMD) that is to 
minimize secondary effects of evolutive diseases. 
 ii- Cystic fibrosis 
In cystic fibrosis a diagnosis made in the early infancy 
allows the introduction of a special diet: studies have 
shown an improvement in the general health and 
growth of the patient. 
The incidence of cystic fibrosis being between 1 in 
2000 to 1 in 4000 births, this screening program has
been adopted by several health authorities. A family 
study and genetic counselling are applied. 
 iii- Duchenne Muscular dystrophy (DMD) 
In muscular dystrophy the advantage of an early 
treatment does not seem as efficient since the age of 
onset of the disease is variable and often the motor 
symptomatology is non specific and may be similar to 
certain orthopedic disorders. In the future an improved 
detection method, reducing positive and negative 
results, would allow to reconsider the indication to 
screen for DMD in the neonatal period. 
 iv- Immunodeficiency virus (HIV) 
The screening for the immunodeficiency virus (HIV) in  
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the neonate is controversial on ethic and clinical 
grounds. Although the early treatment of the newborn 
who is a virus carrier seems to prevent the acquired 
immunodeficiency syndrome several groups contest the 
universal neonatal screening for the virus since there is 
an elevated risk of individual and ethnic discriminat on. 
3- Treatment 
Following biochemical, enzymatic and molecular studies 
that confirm the diagnosis a treatment is applied: 
 i- Dietary restrictions, special products, 
supplements... food banks 
As shown in phenylcetonuria the alimentary restrictions 
and special foods will prevent overloading of 
catabolites deleterious to the child development. 
Protein or specific amino acid restrictions are indicated 
in most metabolic diseases. Food banks are generally 
under the state supervision and are responsible for the 
availability of special foods to the patient. 
 ii- Replacement therapy 
- Organs: the patient may be in need of an organ 
replacement like the liver transplantation in 
hepatorenal tyrosinemia in addition to a special 
diet. However in this particular disease the 
introduction of NTBC ((2-(2nitro-4-
trifluoromethylbezo- yle-1,3-
cyclohexamedione)) stops an enzyme in the 
tyrosine metabolism leading to the decrease of 
succinylacetone that is toxic for the liver and 
responsible for severe neurological effects. This 
therapeutic approach has totally change the 
treatment of this disease in addition to 
eliminating a risky and costly liver transplant, 
and improving the patient well being and 
survival. 
- Enzymes, proteins: the replacement of enzymes 
and proteins is under development and 
evaluation of its therapeutic potential. For 
example a small number of patients suffering 
from Hurler or Hunter diseases, two 
mucopolysaccha-ridoses with a severe prognosis 
have been treated with synthetic enzymes but 
the beneficial effects of this procedure are  
limited. The enzyme replacement therapy 
combined with the recombinant human a-L-
iduronidase in Hurler syndrome is nevertheless 
encouraging and further trials are planned. The 
enzyme replacement thererapy can be done with 
normal bone marrow transplantation from a 
compatible donor. Replacement of proteins like 
globulins and insulin are also good examples of 
replacement therapy.  
 iii- Gene therapy 
The introduction of a gene in a patient, with an 
appropriate vector to correct an abnormal metabolism. 
This domain is under sustained research particularly in 
cancerology and in the study of hereditary degenerativ  
diseases. 
4- Diseases with apparent symptoms during the post 
natal period 
- Hypertrophic cardiopathy 
- acyl-COA deficiency 
- hyperammonemia 
- intermittent leucinosis 
- others… 
One may identify among hereditary diseases those for 
which the symptomatology is absent in the neonatal 
period but appears later during infancy or in 
adolescence and those that have a true late age of onset
during adulthood. 
Among metabolic diseases with late manifestations one 
notes the intermittent leucinosis that has a residual 
enzymatic activity enough to delay the appearance of 
symptoms if there is no increase in intake of food 
containing branched chain aminoacids. An infectious 
disease in the child may trigger typical manifestations 
of this disease commonly called maple syrup urine 
disease because of the urine odour. 
5- Genetic counselling / informed consent 
Access to neonatal screening in a modern society is 
primordial. However for economical reasons or 
expertise disponibility all newborns will not be test d. 
The number of diagnosable diseases has increased in 
recent years and this stresses the importance at least to 
identify populations that are more at risk to develop a 
disease. 
Parents' consent for the screening test is not obligatory 
in all states. There are a number of policies regarding 
the access to the test. According to countries and 
regions a neonatal screening test informed consent may 
be: 
- i. mandatory 
- ii. mandatory with option to refuse the test or 
- iii. optional. 
If the screening test is positive a genetic counselli g is 
offered to parents in view of a future pregnancy and, if 
they agree, to other family members identified as 
individuals at risk. A prenatal diagnosis can also be 
offered if a diagnosis can be reached by studying 
amniotic fluid or cells. 
6- Development 
Who will assume the development cost of these 
programs? In general the state is responsible and must
also see to the follow up of patients who had a positive 
screening test, to the long or short term appropriate 
treatment, and the genetic counselling to be offered to 
the parents of the positively screened individuals. 
The institution or other accredited organism is also 
responsible to the development of screening techniques 
and their validation. 
The use of tandem mass spectrometry leads to new 
therapeutic approaches, increase the survival of 
children for whom a diagnosis is made early who will
eventually rely on the take over by adult medicine 
services. 
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Ethics committees and the scientific community may 
be invited to study the merit of new disease screening 
methods developed and proposed by research groups: it 
is then the duty of ethic committee members to 
formulate an advice in consultation with the population 
on the pertinence of introducing new screening tests. 
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